AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 161 min read$ERNA

Ernexa Therapeutics Inc. (ERNA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Ernexa Therapeutics Inc. (ERNA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 14, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the board of directo

Original reporting
SEC EDGAR 8-K
Published Sep 16, 2026, 8:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 8:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$ERNA
Neutral
high confidence
Mentioned
$ERNA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ERNANeutralLow
01

Why it matters

The filing discloses a new board member without disclosed compensation or related party transactions.

02

Market read

Routine corporate governance update with limited trading relevance.

03

What to watch

Potential future influence if Dr. Spiegel brings biotech expertise.

Relevance 6/10Novelty 3/10Timing: filed Sep 16 2026

Background

Ernexa Therapeutics is a clinical‑stage biotech company.

Company-level read

Ticker impact

$ERNANeutralHigh confidence
Context

Ernexa Therapeutics filed an 8‑K announcing the appointment of Dr. Robert J. Spiegel to its board.

Expected impact

minimal price movement expected

Evidence & confidence

Director appointments are routine corporate actions with limited market effect.

Market effects

Sector

none

Regional

none

Global

none

Counterpoint

What could challenge this read

Unlikely to affect stock price materially.

Key entities

  • company
    Ernexa Therapeutics Inc.

    Biotech firm filing the 8‑K.

  • person
    Robert J. Spiegel, M.D.

    Appointed board member.

Read at source← All news

Related articles

SEP 15
$ERNALowAI 8/10

Ernexa Therapeutics Inc.: Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First

Ernexa Therapeutics (Nasdaq: ERNA) reported positive preclinical data for ERNA-201, showing disease-modifying activity in a rheumatoid arthritis model. The company will focus resources on advancing ERNA-101 for ovarian cancer, aiming for an IND submission by Q4 2026. ERNA-201's results validate the versatility of Ernexa's iMSC platform, which can be engineered for various diseases.

finanznachrichten.de2 min
JUL 15
$ERNAMedAI 8/10

Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy -

Ernexa Therapeutics said an independent study reproduced prior UT Anderson Cancer Center results for its ERNA-101 cell therapy, showing complete tumor clearance and durable long-term survival in a larger cohort. The company reported 10 of 15 animals (67%) cleared tumors with ERNA-101 plus anti-PD-1, while other groups had none. Ernexa targets an IND in Q3 2026 and a phase 1 trial in Q4 2026; shares rose 7.43% to $6.51.

benzinga.com4 min
JUL 15
$ERNAMed

Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry

Ernexa Therapeutics (Nasdaq: ERNA) said an independent CRO reproduced preclinical results for ERNA-101 plus anti-PD-1 in an ovarian cancer model. In 15 treated animals, 10 (67%) had complete tumor clearance and durable long-term survival, while no complete responses occurred in ERNA-101, anti-PD-1, or control arms. The company plans an IND in Q3 2026 and Phase 1 in Q4 2026.

manilatimes.net5 min
JUL 15
$ERNAMedAI 8/10

Ernexa Therapeutics stock surges 30% on preclinical data By Investing.com

Ernexa Therapeutics (NASDAQ:ERNA) shares rose 30% after independent preclinical validation of its lead cell therapy ERNA-101 in ovarian cancer models. According to the company, an independent CRO reproduced earlier results, with ERNA-101 plus anti-PD-1 achieving complete tumor clearance and long-term survival in 10 of 15 animals. The company plans an IND submission in Q3 2026 and Phase 1 in Q4 2026.

investing.com3 min